HUMANA INC HUM

Humana’s most important current source fact is simple: its Medicare products accounted for approximately 86 % of total premiums and services revenue for the three months ended March 31, 2026, according to the company’s 10-Q filed on April 29, 2026. The same filing says all material contracts between Humana and CMS relating to Medicare products had been renewed for 2026, and all product offerings filed with CMS and going to market for 2026 had been approved.

That makes HUM less a vague healthcare ticker and more a public bet on the practical machinery of Medicare Advantage and Medicare Part D Prescription Drug Plan contracts. The official Humana Medicare page supports the product rail, while also drawing a useful legal line: “Humana” is the brand name for plans, products and services provided by subsidiaries and affiliate companies, and plans, products and services are provided by the relevant Humana Entities, not Humana Inc itself.

The latest parsed SEC financial rail is the 10-Q for the period ending March 31, 2026. Humana reported revenues of $39.65B, operating income of $1.75B, net income attributable to parent of $1.19B, diluted EPS of $9.83 and 120.7M diluted weighted average shares. The balance sheet showed $55.28B of assets, $36.63B of liabilities, $18.58B of stockholders’ equity attributable to parent, $4.95B of cash and cash equivalents, and $17.01B of short-term investments. Operating cash flow was $1.25B, while payments to acquire property, plant and equipment were $121.0M.

No TradingView or chart route is supplied in the evidence, so this file cannot claim candles, levels, momentum or volume behaviour. The market mechanism that can be described from the rail is the equity’s dependence on official filings, Medicare contract status, guidance updates and public SEC ownership or insider reporting events.

The named public developments since the 10-Q are mainly filing events: a June 1, 2026 8-K on SEC EDGAR stating that guidance is consistent with the guidance issued in Humana’s April 29, 2026 press release, a May 19, 2026 8-K on SEC EDGAR, a May 14, 2026 Schedule 13G/A, and three Form 4 filings dated May 5, 2026. Those filings matter because they keep the story on official rails, but the supplied pack does not parse the transaction details, ownership percentages or board-level context behind them.

The current tension is therefore narrow but useful: Humana has a large Medicare-centred operating base, a profitable latest parsed quarter, substantial cash and short-term investments, and a filed statement that June guidance remained consistent with the April 29 release. What is not supplied is a price chart, fresh analyst view, claims-cost detail beyond the filing extracts, enrolment trend detail, or the full contents of the May filing events.